Woman’s Life Transformed by Cell Therapy After Battle with Autoimmune Diseases
A 47-year-old woman, who had been grappling with three severe autoimmune diseases for over a decade, has managed to reclaim a nearly normal life following a groundbreaking cell therapy that reset her ailing immune system.
Before undergoing the therapy last year at University Hospital Erlangen in Germany, she had tried nine different treatments, all of which failed to make a lasting difference. At that point, her health was so precarious that she relied on daily blood transfusions and medication to thin her blood.
Remarkably, just weeks after receiving cell therapy, doctors observed a positive reaction to all three of her diseases—an unprecedented occurrence that led to significant improvement in her condition. For the past 14 months, she has been in remission without any treatment and is largely back to her regular life.
Prof. Fabian Müller, who spearheaded the treatment team, described the speed and extent of her recovery as “remarkable,” noting that the therapy has “significantly improved her quality of life.” However, he pointed out that further clinical trials are necessary to understand the long-term effects of the therapy and its potential efficacy on other autoimmune disorders.
This woman had a rare and life-threatening blood condition called autoimmune hemolytic anemia (AIHA), where her immune system mistakenly destroyed her red blood cells. Patients typically require immunosuppressive drugs and regular transfusions, and in her case, traditional treatments no longer worked. “She had no options left and wouldn’t have been able to leave the ward without daily transfusions,” Müller explained.
Alongside AIHA, she faced two additional autoimmune diseases. One, immune thrombocytopenia (ITP), caused her immune cells to attack platelets, increasing bleeding risks. The other, antiphospholipid syndrome (APS), posed a risk of dangerous blood clots. All three conditions stemmed from problematic B-cells, responsible for producing antibodies against infections.
In light of the lack of alternatives, the doctors proposed a therapy known as CAR (chimeric antigen receptor) T-cell therapy, which has revolutionized treatment for certain cancers. They extracted her white blood cells, isolated her T-cells, and engineered them to target a specific protein found on B-cells, then reintroduced them into her body.
The therapy quickly began to take effect, effectively eliminating the rogue B-cells. She had her final blood transfusion just a week after the treatment and was soon engaged in everyday activities two weeks later. Her immune system seemed to stop attacking her red blood cells, and the other autoimmune issues also improved. When her B-cells recovered months afterward, they appeared healthy, indicating that the therapy had reset her immune system. These findings have been documented in the journal Med.
While the woman continues to have a low white blood cell count and slightly elevated liver enzymes, researchers believe these are remnants of her previous treatments rather than side effects of the CAR-T therapy.
Prof. Ben Parker, a rheumatologist at the Kellgren Centre for Rheumatology in Manchester, expressed optimism about the results, noting the apparent improvement across all the patient’s conditions. “The prolonged response off normal therapy suggests there has been an immune reset,” he stated, although the duration of this effect remains uncertain.
Parker, currently leading CAR-T trials for lupus and other autoimmune diseases, mentioned that multiple trials are ongoing for various conditions, including lupus and MS. However, he emphasized that individual case reports do not establish treatment effectiveness for wider use, highlighting the necessity of further clinical trials.
